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ABSTRACT 
The purpose of this study was to prepare PEGylated liposomes containing sildenafil for the treatment of pulmonary arterial hypertension. 
PEGylated liposomes were prepared by thin film hydration method by varying the concentration of lipids. The prepared liposomes were 
characterized for the particle size, PDI, zeta potential, % entrapment efficiency and in-vitro release study. The optimized formulation exhibits a 
particle size of 104.27±1.4 nm, PDI of 0.449±0.02, zeta potential of -42.9±0.7 along with the maximum encapsulation of drug i.e. 87.30±2.6. 
Optimized formulation showed % cumulative drug release of 85.38±0.26 in 48 hr.  From the study it can be concluded that the PEGylated 
liposomes containing sildenafil for the treatment of pulmonary arterial hypertension provides a sustained release of drug and further studies 
are required to confirm their efficacy at clinical level. 
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INTRODUCTION  
Pulmonary arterial hypertension (PAH) is a hemodynamic 
and pathophysiological condition of the lungs exhibiting an 
elevated mean arterial pressure and vascular resistance1. 
The available treatment for PAH including endothelin 
receptor antagonist, calcium antagonist, anticoagulants, 
prostacyclin or inhaled nitrous oxide etc. have several 
associated side effects  such as nausea, vomiting, flushing, 
liver damage etc2.  USFDA have approved sildenafil for the 
treatment of PAH which is a Phosphodiesterase type 
5inhibitor improves blood flow distribution areas and 
reduces resistance at blood vessels3.  
Liposomes or lipid vesicles are colloidal particle composed of 
lipid molecules majorly having at least one enclosed lipid 
bilayer. Liposomes have been considered as an attractive 
drug delivery system for pulmonary application. In spite of 
these facts, a major drawback corresponding to liposomal 
formulation is its rapid clearance from the blood due to 
adherence of plasma protein on phospholipids. To overcome 
this issue, surface of the drug bearing particle is treated with 
PEG of different molecular weight and designated as 
PEGylated liposome which offers release of drug in 
controlled manner4, 5. 
In the present study PEGylated liposomes were prepared and 
characterized for the particle size, PDI, zeta potential, % 
entrapment efficiency and in-vitro release study. 
MATERIAL AND METHODS 
Sildenafil was purchased from Cadila Pharmaceutical, 
Ahmedabad, India. Leciva S-90 was obtained as a gift sample 
from VAV life sciences Pvt Ltd Mumbai, Maharashtra, India. 
Cholesterol was purchased from Sigma-Aldrich Chemical, 
USA. Distilled water (HPLC grade) was purchased from 
Merck specialties Pvt. All other chemicals used were of 
analytical grade. 
Preparation of PEGylated liposomes 
PEGylated liposomes were prepared by thin film hydration 
method by varying the concentration of lipids as shown in 
Table 1. To prepared liposomes firstly the drug and lipid 
were weighed and were taken in round bottom flask and 
dissolved in 5ml of chloroform. Then the RBF was attached 
with the rotary evaporator with the maintained water bath 
temperature at 40°C with 40 rpm. Further organic solvent 
was evaporated to form the thin layers of lipids under 
reduced pressure. Afterwards for the complete removal of 
organic solvent and drying of the lipid film RBF was placed in 
desicator for 2 hr. Then the lipid film was hydrated with the 
20ml of distilled water and Tween 80 on rotary evaporator 
with water bath temperature maintained at 60°C with 100 
rpm untill the lipid film gets completely hydrated to form the 
liposomal suspension. Then the prepared liposomal 
suspension was subjected to probe sonication for two cycles 
of 10 mins so as to reduce the size of the vesicles and then 
kept in refrigerator 5,6. 
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Table 1 Composition of the PEGylated liposome loaded with sildenafil 
Material SL-1 SL-2 SL-3 SL-4 SL-5 SL-6 
Sildenafil (mg) 10 10 10 10 10 10 
Leciva S-90(mg) 180 140 180 140 180 140 
Cholesterol (mg) 10 20 10 20 10 20 
MPEG-DSPE2000(mg) - - 25 25 50 50 
Chloroform (ml) 5 5 5 5 5 5 
Tween80(%w/w) 6 6 6 6 6 6 
Distilled water (ml) 20 20 20 20 20 20 
 
 
Characterization of PEGylated liposomes 
Particle size, PDI, Zeta potential 
Zeta potential, PDI and particle size are very crucial 
parameters for the any developed formulation. Malvern zeta 
sizer ZS (Malvern Instrument UK) based on the principle of 
dynamic light scattering (DLS) was used to measure the 
particle size, zeta potential and PDI of PEGylated liposomes. 
For the determination of particle size, liposomal suspension 
was diluted 1 in 10ml with phosphate buffer saline. PDI was 
determined for evaluation of particle size distribution. Zeta 
potential is expressed as overall charge that the particle 
acquires in a particular medium. It was determined with 
help of Malvern zeta sizer based on the principle of laser 
dopler velocimetry and phase analysis scattering. Zeta 
potential above than +30mv and -30mv are considered as 
more stable7, 8. All the measurements were taken in triplicate 
and expressed in mean ± SD. 
% Entrapment efficiency 
The entrapment efficiency of sildenafil PEGylated liposome 
was measured by the ultracentrifuge method. Entrapment 
efficiency enables to quantify the amount of drug entrapped 
within a liposome. In an outline, vesicular preparations 
containing 1% sildenafil were kept overnight at 4°C and 
centrifuged in a ultracentrifuge (Remi) equipped with TLA-
45 rotor at 4°C on 30 000 rpm for 2 h. The concentration of 
entrapped drug was determined with the help of UV/visible 
spectrophotometer9, 10. The amount of drug entrapped 
within the colloidal system was determined with the help of 
given formula- 
% EE =  
In-vitro drug release study 
The drug release from PEGylated liposomes was 
accomplished with the help of diffusion cell. Prior to work, a 
cellulose acetate membrane was soaked in distilled water for 
24 h, so that it can be effortlessly attached to the donor 
compartment of the diffusion cell. Further, the diffusion cell 
was secured with the help of clamp stand and submerged in 
a receptor compartment containing 100ml of phosphate 
buffer (pH 6.8) maintained at 37°C. Liposomal formulation 
containing single dose equivalent to the sildenafil in donor 
compartment was covered with the help of paraffin so as to 
avoid evaporation of the solvent. The whole assembly was 
kept on magnetic stirrer with continuous stirring at 750rpm. 
3ml of solution was withdrawn and replaced by same 
volume of phosphate buffer in the receptor compartment at 
a specific interval of 0-24h respectively11. The withdrawn 
sample was observed in UV/visible spectrophotometer to 
determine the drug concentration which was further used to 
determine the % cumulative drug release and plotted 
against time12. 
RESULTS AND DISCUSSION 
Particle size and their size distribution are the important 
parameters which describe the quality of liposomal 
formulation and were determined with the help of Malvern 
zeta sizer ZS based on the principle of DLS. The result of 
particle size and PDI was shown in Table 2. All formulations 
i.e. from SL-1 to SL- 6 showed a mean particle size ranging 
from 104.27±1.4 to 137.01±3.7 and PDI ranging from 
0.254±0.04 to 0.449±0.02.  From the obtained results it was 
observed that a small variation in the concentration of lipids 
greatly affects the particle size. As observed that at higher 
concentration of lipid (Leciva S-90) and at lower cholesterol 
concentration minimum particle size was obtained as in 
FormulationSL-3 but at lower concentration of leciva S-90 
and higher concentration particle size was increased. 
According to the results, formulation SL-3 was optimized. 
The stability of the PEGylated liposome was determined by 
zeta potential using Malvern Zeta sizer ZS based on principle 
of laser dopler velocimetry and phase analysis scattering. 
The particles of the liposomal suspension with the value of 
zeta potential above than +30 and -30mv are considered as 
most stable. The result of the zeta potential was shown in 
Table 2. All formulation exhibited the zeta potential ranging 
from -15.2±0.4 to -42.9±0.7. Negative charge on the surface 
of the liposomes was due to the presence of tween-80. The 
results indicate that at higher concentration of leciva S-90 
the zeta potential values were away from zero. These 
findings indicated that stability of the liposomal formulation 
rely on the concentration of lipid used in formulation. A 
proper amount of lipid ratio produces accurate result and 
according to which the formulation SL-3 was optimized. 
% Entrapment efficiency 
Entrapment of drug molecule in the PEGylated liposomes 
depends on the total amount of lipid, total amount of drug 
and drug to the lipids ratio to be added.  % entrapment 
efficiency was determined with the help of centrifugation 
method and the results were shown in Table 2 and Figure 1. 
In the absence of MPEG-DSPE2000 formulation SL 1 and SL 2 
show entrapment of 70.21±2.0 and 68.93±0.8 respectively, 
whereas formulation SL 3 with low concentration of MPEG-
DSPE2000 and cholesterol and high concentration of leciva S-
90 show entrapment of 87.30±2.6 respectively. In addition 
formulation SL 4 with low concentration of leciva S-90 and 
MPEG-DSPE2000 and high concentration of lipids show 
entrapment of 75.32±2.4 respectively whereas formulation 
SL 5 and SL 6 with increased MPEG-DSPE2000 concentration 
show entrapment of 82.65±1.4 and 54.19±0.9 respectively. 
Among all formulations SL 3 show maximum entrapment of 
drug molecules. Result indicates that at higher concentration 
of leciva S-90 entrapment efficiency of liposomes was 
increased.  Tween 80 helps to provide to solubilizing effect 
due to which the amount of sildenafil in the inner aqueous 
phase was increased. At higher concentration of MPEG-
Sharma et al                                                                                                         Journal of Drug Delivery & Therapeutics. 2019; 9(2-s):462-465 
ISSN: 2250-1177                                                                                  [464]                                                                                 CODEN (USA): JDDTAO 
DSPE2000 no significant increase in the entrapment was 
observed because of the increased binding of sildenafil to 
the lipid occurs. Cholesterol helps in lipid bilayer packing 
but at higher concentration lipid membrane packed tightly 
which decreases the entrapment of drug. From the study it 
was concluded that appropriate amount of lipid is necessary 
for the higher encapsulation of drug in the PEGylated 
liposomes. According to the results formulation SL 3 was 
optimized. 
  
Table 2 Characterization of PEGylated liposome of Sildenafil 
characterization SL-1 SL-2 SL-3 SL-4 SL-5 SL-6 
Vesicle size 111.47±2.8 116.38±3.4 104.27±1.4 120.32±1.6 118.39±2.9 137.01±3.7 
PDI 0.312±0.07 0.254±0.04 0.449±0.02 0.267±0.03 0.382±0.06 0.297±0.05 
Zeta potential -28.6±0.4 -24.7±0.3 -42.9±0.7 -15.2±0.4 -36.8±0.2 -30.2±0.6 
%EE 70.21±2.0 68.93±0.8 87.30±2.6 75.32±2.4 82.65±1.4 60.19±0.9 
All data are expressed as mean ± S.D.; n = 3 
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Figure 1: Percentage entrapment efficiency of PEGylated 
liposomal formulations  
In-vitro drug release study 
The in-vitro release of all the formulations loaded with 
sildenafil was studied using diffusion cell. The result of in-
vitro release was depicted in Figure 2. Formulations SL-1 to 
SL-6 showed 68.23±0.25, 63.96±0.67, 85.38±0.26, 
72.65±1.62, 78.14±1.56, 60.19±1.25 drug release in 48 hr 
respectively. Formulation SL-3 showed maximum release 
of drug because of high encapsulation of drug in the 
PEGylated liposome. The release of sildenafil from 
formulation was rapid for initial 2 h and later on it 
followed sustained release and when the concentration of 
leciva S 90 was increased then the release of drug reduces 
because the drug was entrapped in the phospholipid 
bilayer membrane and the membrane was stabilized with 
cholesterol and tween 80 so the drug takes time to get 
released. Thus a depot effect was achieved for the release 
of drug from the PEGylated liposome. The formulation SL 6 
showed minimum release of drug in 24h because of low 
encapsulation and presence of high concentration of 
MPEG-DSPE2000 and cholesterol. From this study, it was 
concluded that small variations in the concentration of 
lipids may produces a drastic variation in the release of 
drug. According to the results, formulation SL-3 showed 
sustained release of drug and was optimized formulation. 
This factor was further supported by observation of Shavi 
et al. 2015; and Dave et al. 2017. 
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Figure 2: In-vitro drug releases of PEGylated liposomal 
formulations  
CONCLUSION  
In the present PEGylated liposomes were prepared by thin 
film hydration method with varying lipid concentration. 
Result shows a controlled particle size, good zeta potential 
which indicates that the formulation was stable along with 
maximum encapsulation of drug in the liposomes. 
Optimized formulation show a maximum release of drug in 
48 hr which show that the PEGylated liposomes provide a 
sustained release of sildenafil for the treatment of 
pulmonary arterial hypertension. Further in-vivo study and 
more research work are needed to bring the PEGylated 
liposomes into its clinical realization.  
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